Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Trends in Psychiatry and Psychotherapy |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-60892020000100048 |
Resumo: | Abstract Introduction The opioid epidemic is a severe problem in the world, especially in the United States, where prescription opioid overdose accounts for a quarter of drug overdose deaths. Objective To describe psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in the United States. Methods We conducted a retrospective cross-sectional study of the 2016 Medicare Part D claims data and analyzed psychiatrists’ prescriptions of: 1) opioids; 2) benzodiazepines, whose concurrent prescription with opioids can cause overdose death; 3) buprenorphine, a partial opioid agonist for treating opioid addiction; 4) and naltrexone microsphere, a once-monthly injectable opioid antagonist to prevent relapse to opioid dependence. Prescribers with 11 or more claims were included in the analysis. Results In Medicare Part D in 2016, there were a total of 1,131,550 prescribers accounting for 1,480,972,766 total prescriptions and 78,145,305 opioid prescriptions, including 25,528 psychiatrists (2.6% of all prescribers) accounting for 44,684,504 total prescriptions (3.0% of all prescriptions) and 131,115 opioid prescriptions (0.2% of all opioid prescriptions). Psychiatrists accounted for 17.3% of benzodiazepine, 16.3% of buprenorphine, and 33.4% of naltrexone microsphere prescriptions. The opioid prescription rate of psychiatrists was much lower than that of all prescribers (0.3 vs 5.3%). The buprenorphine prescription rate of psychiatrists was much higher than that of all prescribers (2.3 vs. 0.1%). There was a substantial geographical variation across the United States. Conclusions The results show that, proportionally, psychiatrists have lower rates of opioid prescription and higher rates of benzodiazepine and buprenorphine prescription. |
id |
APRGS-1_20f015ffbf954afda63007cc02fa7b1f |
---|---|
oai_identifier_str |
oai:scielo:S2237-60892020000100048 |
network_acronym_str |
APRGS-1 |
network_name_str |
Trends in Psychiatry and Psychotherapy |
repository_id_str |
|
spelling |
Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United StatesPsychiatryaddictiongeriatric psychiatryopioidaddiction treatmentAbstract Introduction The opioid epidemic is a severe problem in the world, especially in the United States, where prescription opioid overdose accounts for a quarter of drug overdose deaths. Objective To describe psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in the United States. Methods We conducted a retrospective cross-sectional study of the 2016 Medicare Part D claims data and analyzed psychiatrists’ prescriptions of: 1) opioids; 2) benzodiazepines, whose concurrent prescription with opioids can cause overdose death; 3) buprenorphine, a partial opioid agonist for treating opioid addiction; 4) and naltrexone microsphere, a once-monthly injectable opioid antagonist to prevent relapse to opioid dependence. Prescribers with 11 or more claims were included in the analysis. Results In Medicare Part D in 2016, there were a total of 1,131,550 prescribers accounting for 1,480,972,766 total prescriptions and 78,145,305 opioid prescriptions, including 25,528 psychiatrists (2.6% of all prescribers) accounting for 44,684,504 total prescriptions (3.0% of all prescriptions) and 131,115 opioid prescriptions (0.2% of all opioid prescriptions). Psychiatrists accounted for 17.3% of benzodiazepine, 16.3% of buprenorphine, and 33.4% of naltrexone microsphere prescriptions. The opioid prescription rate of psychiatrists was much lower than that of all prescribers (0.3 vs 5.3%). The buprenorphine prescription rate of psychiatrists was much higher than that of all prescribers (2.3 vs. 0.1%). There was a substantial geographical variation across the United States. Conclusions The results show that, proportionally, psychiatrists have lower rates of opioid prescription and higher rates of benzodiazepine and buprenorphine prescription.Associação de Psiquiatria do Rio Grande do Sul2020-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-60892020000100048Trends in Psychiatry and Psychotherapy v.42 n.1 2020reponame:Trends in Psychiatry and Psychotherapyinstname:Sociedade de Psiquiatria do Rio Grande do Sulinstacron:APRGS10.1590/2237-6089-2019-0015info:eu-repo/semantics/openAccessPan,KevinSilver,ShawgiDavis,Charleseng2020-05-14T00:00:00Zoai:scielo:S2237-60892020000100048Revistahttp://www.scielo.br/scielo.php?script=sci_serial&pid=2237-6089&lng=en&nrm=isohttps://old.scielo.br/oai/scielo-oai.phprevista@aprs.org.br|| rodrigo_grassi@terra.com.br2238-00192237-6089opendoar:2020-05-14T00:00Trends in Psychiatry and Psychotherapy - Sociedade de Psiquiatria do Rio Grande do Sulfalse |
dc.title.none.fl_str_mv |
Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States |
title |
Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States |
spellingShingle |
Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States Pan,Kevin Psychiatry addiction geriatric psychiatry opioid addiction treatment |
title_short |
Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States |
title_full |
Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States |
title_fullStr |
Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States |
title_full_unstemmed |
Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States |
title_sort |
Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States |
author |
Pan,Kevin |
author_facet |
Pan,Kevin Silver,Shawgi Davis,Charles |
author_role |
author |
author2 |
Silver,Shawgi Davis,Charles |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Pan,Kevin Silver,Shawgi Davis,Charles |
dc.subject.por.fl_str_mv |
Psychiatry addiction geriatric psychiatry opioid addiction treatment |
topic |
Psychiatry addiction geriatric psychiatry opioid addiction treatment |
description |
Abstract Introduction The opioid epidemic is a severe problem in the world, especially in the United States, where prescription opioid overdose accounts for a quarter of drug overdose deaths. Objective To describe psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in the United States. Methods We conducted a retrospective cross-sectional study of the 2016 Medicare Part D claims data and analyzed psychiatrists’ prescriptions of: 1) opioids; 2) benzodiazepines, whose concurrent prescription with opioids can cause overdose death; 3) buprenorphine, a partial opioid agonist for treating opioid addiction; 4) and naltrexone microsphere, a once-monthly injectable opioid antagonist to prevent relapse to opioid dependence. Prescribers with 11 or more claims were included in the analysis. Results In Medicare Part D in 2016, there were a total of 1,131,550 prescribers accounting for 1,480,972,766 total prescriptions and 78,145,305 opioid prescriptions, including 25,528 psychiatrists (2.6% of all prescribers) accounting for 44,684,504 total prescriptions (3.0% of all prescriptions) and 131,115 opioid prescriptions (0.2% of all opioid prescriptions). Psychiatrists accounted for 17.3% of benzodiazepine, 16.3% of buprenorphine, and 33.4% of naltrexone microsphere prescriptions. The opioid prescription rate of psychiatrists was much lower than that of all prescribers (0.3 vs 5.3%). The buprenorphine prescription rate of psychiatrists was much higher than that of all prescribers (2.3 vs. 0.1%). There was a substantial geographical variation across the United States. Conclusions The results show that, proportionally, psychiatrists have lower rates of opioid prescription and higher rates of benzodiazepine and buprenorphine prescription. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-60892020000100048 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-60892020000100048 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/2237-6089-2019-0015 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação de Psiquiatria do Rio Grande do Sul |
publisher.none.fl_str_mv |
Associação de Psiquiatria do Rio Grande do Sul |
dc.source.none.fl_str_mv |
Trends in Psychiatry and Psychotherapy v.42 n.1 2020 reponame:Trends in Psychiatry and Psychotherapy instname:Sociedade de Psiquiatria do Rio Grande do Sul instacron:APRGS |
instname_str |
Sociedade de Psiquiatria do Rio Grande do Sul |
instacron_str |
APRGS |
institution |
APRGS |
reponame_str |
Trends in Psychiatry and Psychotherapy |
collection |
Trends in Psychiatry and Psychotherapy |
repository.name.fl_str_mv |
Trends in Psychiatry and Psychotherapy - Sociedade de Psiquiatria do Rio Grande do Sul |
repository.mail.fl_str_mv |
revista@aprs.org.br|| rodrigo_grassi@terra.com.br |
_version_ |
1754209281566048256 |